The Life Sciences sector includes companies involved in biopharmaceuticals, medical manufacturing and distribution, and bio products.
The Issuer is in the business of cannabis cultivation, production and dispensaries. The Issuer also has a patented proprietary method of extracting various cannabinoids from the marijuana plant and converting them into products with a higher level of quality and consistency.
Cognetivity Neurosciences Ltd. is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA) for use in medical and commercial environments. Cognetivity’s ICA uses Artificial Intelligence and machine learning techniques to help detect the earliest signs of impairment by testing the performance of large areas of the brain, potentially allowing early diagnosis of dementia. Cognetivity aims to develop the ICA through planned clinical studies to the market in North America and Europe.
Columbia Care is one of the largest and most experienced cultivators, manufacturers and providers of medical and adult use cannabis products and related services with licenses in 19 jurisdictions in the US and the EU. Columbia Care has completed more than 1.6 million sales transactions since inception and working in collaboration with renowned and innovative teaching hospitals and medical centers globally, continues to be a patient-centered health and wellness company setting the standard for compassion, professionalism, quality, care and innovation in the rapidly expanding cannabis industry.
CordovaCann Corp. is a Canadian-domiciled cannabis-focused consumer products company. CordovaCann primarily provides services and investment capital to the processing and production vertical markets of the cannabis industry.
Core One Labs Inc. is a technology company that licenses its technology to a state-of-the-art production and packaging facility located in Southern California. The Company’s technology produces infused strips (similar to breath strips) that are not only a safer, healthier option to other forms of delivery but also superior bioavailability of cannabis constituents. Some strips will also include supplemental co-active ingredients such as nutraceuticals, vitamins and peptides. The technology provides a new way to accurately meter the dosage and assure the purity of selected product. From start to finish, the production process, based on the Company’s technology, tests for quality and composition of all the ingredients used in each and every strip which results in a delivery system that is safe, consistent and effective. In addition, through its efforts to develop a better CannaStripsTM product, the Company has developed considerable expertise in cannabis extraction and nursery activities. The operational expertise developed by the Company as a result of these efforts has created new market opportunities for the Company in white label sales.
Cresco Labs also announced that it has entered into an agreement with a group of investment dealers, led by Canaccord Genuity Corp. (the “Underwriters”), pursuant to which the Underwriters will purchase, on a underwritten basis pursuant to the filing of a shelf prospectus supplement, an aggregate of 7,350,000 units (the “Units”) of the Company at a price of C$10.00 per Unit (the “Offering Price”) for aggregate gross proceeds of C$73,500,000 (the “Offering”).
Each Unit will be comprised of one subordinate voting share of the Company (a “Share”) and one half of one subordinate voting share purchase warrant of the Company (each full warrant, a “Warrant”). Each Warrant will entitle the holder to acquire one subordinate voting share of the Company (the “Underlying Shares”) at a price of C$12.50 per Underlying Share, subject to adjustment in certain events (the “Exercise Price”), for a period of 3 years following the Closing Date (as hereinafter defined). The Company intends to apply to list the Warrants on the Canadian Securities Exchange.
Cresco Labs is one of the largest vertically-integrated multi-state cannabis operators in the United States. Cresco Labs is built to become the most important company in the cannabis industry by combining the most strategic geographic footprint with one of the leading distribution platforms in North America. Employing a consumer-packaged goods (“CPG”) approach to cannabis, Cresco Labs’ house of brands is designed to meet the needs of all consumer segments and includes some of the most recognized and trusted national brands including Cresco, Remedi and Mindy’s, a line of edibles created by James Beard Award-winning chef Mindy Segal. Sunnyside*, Cresco Labs’ national dispensary brand, is a wellness-focused retailer designed to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs has launched the industry’s first national comprehensive Social Equity and Educational Development (SEED) initiative designed to ensure that all members of society have the skills, knowledge and opportunity to work in and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.
(Note: In addition to the 73,531,939 Subordinate Voting Shares that are issued and outstanding, there are 210,425,980 Subordinate Voting Shares reserved for issuance pursuant to the redemption and conversion rights attached to: (i) the outstanding Proportionate Voting Shares of Cresco Labs Inc. that are not listed, and (ii) certain outstanding securities of Cresco Labs, LLC, which is a subsidiary of Cresco Labs, Inc. The total number of equity shares assuming all are converted into the listed class would be 281,703,424.)
Curaleaf Holdings, Inc., its subsidiaries and managed entities are directly engaged in the manufacture, possession, use, sale or distribution of cannabis and/or hold licenses in the adult-use and/or medicinal cannabis marketplace in the States of Arizona, Connecticut, Florida, Maine, Maryland, Massachusetts, Nevada, New Jersey, New York and Oregon.
Investor Note: In addition to the 439,753, 531 Subordinate Voting Shares that are listed and trading, there are 93,970,705 shares reserved specifically for issuance pursuant to the conversion rights attached to the Multiple Voting Shares that are issued and outstanding but not listed. The total number of issued shares assuming all Multiple Voting Shares are converted into the listed class would be 533,724,236.
Dixie Brands Inc. manages, protects and promotes a portfolio of licensed intellectual property and commercialization of proprietary processes and products related to the DIXIETM brand. Dixie Brands Inc. is actively engaged in the licensing of proprietary bases, essences, and other prepared ingredients, the formula of which is an industrial secret of Dixie Brands Inc.
Advertisement
Publicité
Advertisement
Publicité
